北陸藥業(300016.SZ):釓貝葡胺注射劑、釓噴酸葡胺注射劑擬中選集中帶量採購
格隆匯6月27日丨北陸藥業(300016.SZ)公佈,近日,北京北陸藥業股份有限公司參加了新疆維吾爾自治區二十六省聯盟藥品集中帶量採購工作,根據新疆維吾爾自治區醫療保障局發佈的《二十六省聯盟藥品集中帶量採購綜合評審擬中選結果公示》顯示,公司釓貝葡胺注射劑、釓噴酸葡胺注射劑擬中選本次集中帶量採購。
本次擬中選產品之一釓噴酸葡胺注射劑,是公司自1992年推出的第一支釓類對比劑,長期以來一直是公司營業收入和業績的重要來源。2024年度,釓噴酸葡胺注射劑實現銷售收入23,619.76萬元,佔公司當期營業收入的比例為24.01%。另一款擬中選產品釓貝葡胺注射劑於2024年通過一致性評價,截至公吿日,該產品基本未進行銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.